Ticker brief
DSGN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
5
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-23 → 2026-07-02 · now +0.00 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 2 | +0.18 |
| @SpxSlayers | C | -0.33 | 1 | +0.10 |
| @joinlegendsonly | C | +0.63 | 1 | +0.00 |
| @PrismMarketView | C | · | 1 | +0.25 |
| @Quantumup1 | C | -1.95 | 1 | +0.00 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @Quantumup1 | +0.00 | H.C. Wainwright assumed LRMR coverage at Buy with $10 PT and launch/sales forecasts. | · | tweet ↗ |
| 2026-07-01 | @OzmosiHealth | +0.10 | Design Therapeutics announced planned Phase 1 DM1 results in YE27. | · | tweet ↗ |
| 2026-06-30 | @PrismMarketView | +0.25 | DSGN begins patient dosing in Phase 1 DT-818 trial. | · | tweet ↗ |
| 2026-06-30 | @OzmosiHealth | +0.25 | Design Therapeutics initiates patient dosing in Phase 1 multiple ascending dose trial of DT-818. | · | tweet ↗ |
| 2026-06-27 | @joinlegendsonly | +0.00 | Weekly overview recaps winners and lists next week's watch tickers. | · | tweet ↗ |
| 2026-06-23 | @SpxSlayers | +0.10 | Market analysis gives DSGN reclaim and breakdown levels. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.